- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.12.25 | IMMUCELL CORP /DE/ - 8-K, Current Report | - | SEC Filings | ||
| IMMUCELL Aktie jetzt für 0€ handeln | |||||
| 26.12.25 | ImmuCell Puts Re-Tain On Pause After FDA Letter | 3 | Benzinga.com | ||
| 24.12.25 | ImmuCell shifts focus to First Defense after FDA setback for Re-Tain | 1 | Investing.com | ||
| 24.12.25 | ImmuCell: Strategiewechsel nach FDA-Rückschlag für Re-Tain | 1 | Investing.com Deutsch | ||
| 24.12.25 | ImmuCell Corporation: ImmuCell Announces Strategic Focus on First Defense After Receiving an FDA Incomplete Letter for Re-Tain | 996 | GlobeNewswire (Europe) | PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health... ► Artikel lesen | |
| 14.11.25 | ImmuCell signals operational excellence and targets $30M annual production capacity amid management transition | 2 | Seeking Alpha | ||
| 14.11.25 | ImmuCell Q3 2025 slides: Improved margins despite revenue dip, Re-Tain awaits FDA | 2 | Investing.com | ||
| 14.11.25 | ImmuCell: Margen steigen trotz Umsatzrückgang - Warten auf FDA-Zulassung für Re-Tain | 11 | Investing.com Deutsch | ||
| 04.11.25 | ImmuCell appoints Olivier te Boekhorst as new CEO | 1 | Investing.com | ||
| 07.10.25 | ImmuCell announces preliminary sales results for Q3 | 1 | Seeking Alpha | ||
| 07.10.25 | ImmuCell Corporation: ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025 | 108 | GlobeNewswire (Europe) | PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| 07.10.25 | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09.25 | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09.25 | ImmuCell names Olivier te Boekhorst as new president and CEO | 1 | Investing.com | ||
| 29.09.25 | ImmuCell Corporation: ImmuCell Announces Selection of its Next President and CEO | 146 | GlobeNewswire (Europe) | PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen | |
| 25.08.25 | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| 15.08.25 | ImmuCell outlines cautious H2 outlook as capacity expansion supports First Defense suite | 4 | Seeking Alpha | ||
| 14.08.25 | IMMUCELL CORP /DE/ - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08.25 | IMMUCELL CORP /DE/ - 8-K, Current Report | 4 | SEC Filings | ||
| 12.08.25 | ImmuCell Corporation: ImmuCell Announces Bank Debt Refinancing | 2.708 | GlobeNewswire (Europe) | PORTLAND, Maine, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,290 | +8,86 % | Evotec, K+S, Puma, Redcare Pharmacy, Renk, Vossloh - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BB BIOTECH | 48,800 | +3,83 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| QIAGEN | 40,245 | +0,65 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| AMGEN | 293,00 | +3,74 % | Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar | DJ Amgen übernimmt Dark Blue für bis zu 840 Millionen Dollar
Von Colin Kellaher
DOW JONES--Amgen hat das britische Biotechnologieunternehmen Dark Blue Therapeutics für bis zu 840 Millionen... ► Artikel lesen | |
| NOVAVAX | 6,591 | +3,60 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| BIOGEN | 159,85 | +2,27 % | Analyst Expectations For Biogen's Future | ||
| ILLUMINA | 128,80 | +2,32 % | Illumina startet neue Cloud-Plattform für Multiomik-Datenanalyse | ||
| REGENERON PHARMACEUTICALS | 695,80 | +4,73 % | 21 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know | ||
| INOVIO PHARMACEUTICALS | 1,450 | +5,84 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,366 | +2,71 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,770 | +5,18 % | Intellia Stock Declines Around 55% in 3 Months: Here's Why | ||
| COSCIENS BIOPHARMA | 1,600 | 0,00 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| SCORPIUS | 0,070 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| BIOCRYST PHARMACEUTICALS | 6,810 | +5,22 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOMARIN PHARMACEUTICAL | 52,36 | +1,87 % | H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver |
Das Unternehmen IMMUCELL CORPORATION kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,350 Euro und damit +4,90 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUCELL CORPORATION finden Sie auf Wallstreet Online.